• Citer

EORTC 10941: A phase II study of liarozole in postmenopausal patients with 'chemotherapy-resistant' or 'potentially hormone sensitive' metastatic breast cancer.

par Hamilton, Andrew;Roy, J A;Beex, Louk;Piccart-Gebhart, Martine ;Mauriac, L;Coleman, R;Paridaens, R. ;Boes, G H;Van Vreckem, Ann;Palmer, P;Klijn, J
Référence Breast cancer research and treatment, 60, 2, page (181-188)
Publication Publié, 2000-03

Article révisé par les pairs

• Détails
• Contenu

Titre:	EORTC 10941: A phase II study of liarozole in postmenopausal patients with 'chemotherapy-resistant' or 'potentially hormone sensitive' metastatic breast cancer.
Auteur:	Hamilton, Andrew; Roy, J A; Beex, Louk; Piccart-Gebhart, Martine; Mauriac, L; Coleman, R; Paridaens, R.; Boes, G H; Van Vreckem, Ann; Palmer, P; Klijn, J
Informations sur la publication:	Breast cancer research and treatment, 60, 2, page (181-188)
Statut de publication:	Publié, 2000-03
Sujet CREF:	Sciences bio-médicales et agricoles
MeSH keywords:	Adult
	Aged
	Antineoplastic Agents, Hormonal -- adverse effects
	Antineoplastic Agents, Hormonal -- pharmacology
	Antineoplastic Agents, Hormonal -- therapeutic use
	Breast Neoplasms -- chemistry
	Breast Neoplasms -- drug therapy
	Breast Neoplasms -- pathology
	Disease-Free Survival
	Drug Resistance, Neoplasm
	Female
	Humans
	Imidazoles -- adverse effects
	Imidazoles -- pharmacology
	Imidazoles -- therapeutic use
	Middle Aged
	Postmenopause
	Receptors, Estrogen -- analysis
	Treatment Outcome
Note générale:	Clinical Trial
	Clinical Trial, Phase II
	Journal Article
	Multicenter Study
	Research Support, Non-U.S. Gov't
Langue:	Anglais
Identificateurs:	urn:issn:0167-6806
	info:pmid/10845281